Rayvolve LN

Rayvolve LN is a computer-aided detection software designed to enhance radiologists' ability to identify pulmonary nodules on frontal chest radiographs as a second reader. Its effectiveness is validated by improved diagnostic accuracy, sensitivity, and specificity demonstrated in clinical studies, supporting its substantial equivalence and regulatory approval as a Class II medical image analyzer.

AZmed's device, Rayvolve LN, is a computer-aided detection software developed to assist radiologists in identifying and marking suspected pulmonary nodules between 6 and 30mm on frontal (AP/PA) chest radiographs. Intended for use as a second reader for patients 18 years or older on digital radiographic systems, the device is compatible with DICOM Node servers and provides adjunctive information without replacing the original image. A recent review determined that this Class II medical image analyzer is substantially equivalent to a legally marketed predicate device for its specified indications for use, permitting its marketing. The device's marketing is subject to standard regulatory controls, encompassing requirements for annual registration, device listing, quality systems, labeling, and post-market reporting. Comprehensive performance data, including software verification, validation, and bench testing, supported the device's design and intended function. A clinical study further demonstrated that radiologists' diagnostic accuracy, sensitivity, and specificity improved when aided by Rayvolve LN. These evaluations confirm that the device performs comparably to the predicate device, ensuring equivalent safety, performance, and effectiveness.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the algorithm within Rayvolve LN differentiate between true pulmonary nodules and other radiopaque structures or artifacts on chest radiographs?; What were the specific demographic characteristics of the patient cohort in the clinical study, and how might these influence the generalizability of the device's performance?; Beyond diagnostic accuracy, sensitivity, and specificity, were there any metrics related to workflow efficiency or reduction in reading time for radiologists using Rayvolve LN?; What is the long-term plan for post-market surveillance and reporting, particularly concerning the identification of potential false positives or false negatives that might arise in real-world clinical settings?; Given its 'second reader' role, what specific training or guidance is recommended for radiologists to optimally integrate Rayvolve LN's adjunctive information into their diagnostic process?